Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

Fig. 2

Baseline immune infiltrates in responders and non-responders. Eleven patients had baseline specimens available for immunohistochemistry. a Percentage of positive CD8, CD45-RO, Granzyme B, and PD-1 TILs in tumor specimens corresponding to responders (R) and non-responders (NR) patients. b Representative images of tissue sections from responders (R) and non-responders (NR) patients showing subsets of TILs expressing CD8, CD-45RO, PD-1 (× 100) and Granzyme B (× 200) (immunohistochemistry)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us